| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/26/2001 | WO2001021137A8 Extracts of orange peel for prevention and treatment of cancer |
| 07/26/2001 | WO2001019811A3 N-arymethylthioanilide compounds useful for the inhibition of the replication of hiv |
| 07/26/2001 | WO2001017543A3 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 07/26/2001 | WO2001015726A3 Compositions for stimulating cytokine secretion and inducing an immune response |
| 07/26/2001 | WO2001014886A3 Inhibitors of binding between proteins and macromolecular ligands |
| 07/26/2001 | WO2001014415A3 Egfh2 genes and gene products |
| 07/26/2001 | WO2001013891A3 Modulation of release from dry powder formulations |
| 07/26/2001 | WO2001010902A8 Nucleoc acids and secreted polypeptides encoded thereby |
| 07/26/2001 | WO2001008663A3 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 07/26/2001 | WO2001002601A3 Cell-based assay systems for examining hcv ns3 protease activity |
| 07/26/2001 | WO2000078939A3 Vectors for the treatment of tumors by gene therapy |
| 07/26/2001 | WO2000070341A3 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 07/26/2001 | WO2000069445A8 Combination therapy for treating hypercholesterolemia |
| 07/26/2001 | WO2000068183A3 High purity (1r,2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them |
| 07/26/2001 | WO2000056342A3 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity |
| 07/26/2001 | WO2000055194A9 Tuberculosis antigens and methods of use therefor |
| 07/26/2001 | WO2000041566A9 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/26/2001 | WO2000038664A3 Amine condensation polymer bile acid sequestrants |
| 07/26/2001 | WO2000015178A3 Computer implemented pharmacokinetics method and program |
| 07/26/2001 | WO1999064040A8 Novel polyene macrolide compounds and uses |
| 07/26/2001 | US20010009995 Oxybutynin therapy |
| 07/26/2001 | US20010009962 One pot process for preparing sildenafil (drug for erectile dysfunction) and derivatives by reacting for example 4-(2-methoxy-5-(4-methyl-1-piperazinylsulfonyl)benzamido)-1-methyl-3-propyl -1H-pyrazole-5-carboxamide with ethanol |
| 07/26/2001 | US20010009926 Mesozeaxanthin formulations for treatment of retinal disorders |
| 07/26/2001 | US20010009924 Methods of providing symptomatic and prophylactic neuroprotection |
| 07/26/2001 | US20010009923 Salt with pamoic acid, used in treatment of myocardial ischemia, angina pectoris, heart failure and arrhythmias; muscular asthenia and cramps; as food supplement, dietetic |
| 07/26/2001 | US20010009922 An agent to induce expressioon of a product, e.g. thymidinekinase, in viral-infected cell to increase the sensitivity to the viricide whose activity is directed to the expressed product; antiproliferative agent |
| 07/26/2001 | US20010009921 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 07/26/2001 | US20010009920 Combination therapy for osteoporosis |
| 07/26/2001 | US20010009919 Tris benzimidazoles; fungicides, anticarcinogenic agents, enzyme inhibitor |
| 07/26/2001 | US20010009918 Composition and method for treating allergic diseases |
| 07/26/2001 | US20010009917 Reducing associated adverse effects; 5-lipoxygenase inhibitor, useful in treatment of conditions related to elevated leukotriene levels |
| 07/26/2001 | US20010009915 Nitrogen oxide yielding and thromboxane A2 (TXA2) and serotonin (5HT2) receptor antagonist; treatment of atherothrombotic cardiovascular disorders |
| 07/26/2001 | US20010009914 Acridone-derived compounds useful as antineoplastic and antiretroviral agents |
| 07/26/2001 | US20010009913 Anxiety method |
| 07/26/2001 | US20010009911 Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress |
| 07/26/2001 | US20010009910 Administering calcium antagonist and reducing calcium pyrophosphate crystal deposition in an animal with pyrophosphate gout or osteoarthritis; diltiazem, nifedipine |
| 07/26/2001 | US20010009908 To preserve viable tissue, especially the integrity of the endothelial layer, after removal from donor and prior to penetrating keroplasty; vision defects therapy |
| 07/26/2001 | US20010009907 Compositions and methods for preventing restenosis following revascularization procedures |
| 07/26/2001 | US20010009906 Treatment of HIV-infected human in alternation or combination with second anti-HIV drug that induces mutation pattern at other than 70th codon of reverse transcriptase region location; drug resistance, pharmokinetics |
| 07/26/2001 | US20010009903 Roasting process using far infrared radiation, microorganism fermentation to produce peroxide lipid thereby improving antitumor activity |
| 07/26/2001 | US20010009900 Breast cancer, increase insulin receptor phosphorylation in Type II diabetics |
| 07/26/2001 | US20010009899 Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects |
| 07/26/2001 | US20010009679 Fat soluble vitamin dispersed in a matrix of an emulsion-forming natural polysaccharide gum and/or a protein; beverages, tablets, cosmetics; powder in form of nanoparticles |
| 07/26/2001 | US20010009678 Drug such as lansoprazole, voglibose, or candesartan cilexetil, water soluble sugar alcohol, and low-substituted hydroxypropyl cellulose; tablet with improved buccal disintegration or dissolution |
| 07/26/2001 | US20010009677 Sterol esters in tableted solid dosage forms |
| 07/26/2001 | US20010009673 For controlled release of gestagens such as levonorgestrel, and optionally estrogen in a matrix of an N-vinyllactam copolymer with acrylic acids, esters and amides, and/or vinyl esters; steroids do not crystallize out, storage stability |
| 07/26/2001 | US20010009671 For regulating the oily and/or shiny appearance of skin; comprising a panthenol oil regulating agent, a particulate, oil-absorbing polymer such as crosslinked ethylene glycol dimethacrylate-allyl ether copolymer, and a carrier |
| 07/26/2001 | US20010009670 Parenterally administering large liposomes comprised of phospholipids substantially free of sterol, where the liposomes pick-up cholesterol |
| 07/26/2001 | US20010009662 AB block polymers, comprising a polylactone part made from monomers such as lactic acid, and B is derived from hydroxyl, amine, or carboxyl terminated compound endcapped with nonreactive group; storage stablity; anti-adhesions |
| 07/26/2001 | US20010009661 Preparing an iodine demand disinfectant by contacting at high temperature and pressure a porous strong base anion exchange resin in salt form with iodine or polyiodide ion absorbable by the resin to form the polyiodide-resin |
| 07/26/2001 | DE19954357A1 Composition useful for filling out tissue, such as for cosmetic purposes or for treatment of wounds, is biocompatible and includes, dextran beads coated with hyaluronic acid |
| 07/26/2001 | DE19954321A1 Erleichterte Verabreichung von alpha-Liponsäure oder Derivaten derselben Ease of administration of alpha-lipoic acid or derivatives thereof |
| 07/26/2001 | DE10100779A1 Formulierung Formulation |
| 07/26/2001 | DE10037590A1 Natural plant disinfectant and its preparation |
| 07/26/2001 | DE10002510A1 New phenylamidine compounds are useful for the treatment of thrombosis, cerebrovascular disorders, heart infarction, arteriosclerosis, osteoporosis, tumor metastasis, shock and diabetes |
| 07/26/2001 | DE10002509A1 New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
| 07/26/2001 | DE10002304A1 Use of 1,1-dioxoperhydro-1,2,4-thiadazine derivatives for the topical treatment of neurodermatitis provides effective treatment without skin irritation |
| 07/26/2001 | DE10001729A1 Treatment or prevention of hepatitis C infection by administration of certain bicyclic compounds, e.g. 2-methyl-1,4-naphthoquinone |
| 07/26/2001 | DE10000577A1 Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity |
| 07/26/2001 | CA2673615A1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/26/2001 | CA2479511A1 Compositions and methods for the treatment of tumor |
| 07/26/2001 | CA2479498A1 Compositions and methods for the treatment of tumor |
| 07/26/2001 | CA2406732A1 Anxiety method |
| 07/26/2001 | CA2400803A1 Ocular growth and nicotinic antagonists |
| 07/26/2001 | CA2398695A1 Chondromodulin-i related peptide |
| 07/26/2001 | CA2398409A1 Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
| 07/26/2001 | CA2398388A1 Novel piperidine compound and pharmaceutical thereof |
| 07/26/2001 | CA2398343A1 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | CA2398086A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis |
| 07/26/2001 | CA2398061A1 Substituted glutarimides and their use as inhibitors of il-12 production |
| 07/26/2001 | CA2397919A1 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
| 07/26/2001 | CA2397871A1 Novel podophyllotoxin compositions |
| 07/26/2001 | CA2397863A1 Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| 07/26/2001 | CA2397848A1 Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof |
| 07/26/2001 | CA2397830A1 Compositions for the prevention of diaper dermatitis |
| 07/26/2001 | CA2397802A1 Calcilytic compounds |
| 07/26/2001 | CA2397793A1 Combination of temozolomide and pegylated interferon-alpha for treating cancer |
| 07/26/2001 | CA2397792A1 Cochleate formulations and their use for delivering biologically relevant molecules |
| 07/26/2001 | CA2397783A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | CA2397781A1 Compositions with enhanced oral bioavailability |
| 07/26/2001 | CA2397774A1 Jak/stat pathway inhibitors and the uses thereof |
| 07/26/2001 | CA2397726A1 Methods for the treatment of substance abuse |
| 07/26/2001 | CA2397686A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | CA2397665A1 Alpha v integrin receptor antagonists |
| 07/26/2001 | CA2397659A1 Statin-type bone growth stimulators |
| 07/26/2001 | CA2397633A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | CA2397627A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 07/26/2001 | CA2397598A1 Combinations for treating neoplasms |
| 07/26/2001 | CA2397597A1 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| 07/26/2001 | CA2397571A1 Apoptin-associating protein |
| 07/26/2001 | CA2397565A1 Food product and process |
| 07/26/2001 | CA2397543A1 Gamma-secretase inhibitors |
| 07/26/2001 | CA2397533A1 Substituted phenylamidines, pharmaceutical compositions containing these compounds and processes for preparation thereof |
| 07/26/2001 | CA2397531A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same |
| 07/26/2001 | CA2397492A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | CA2397333A1 Local drug delivery using photosensitizer-mediated and electromagnetic radiation-enhanced vascular permeability |
| 07/26/2001 | CA2397324A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom |
| 07/26/2001 | CA2397205A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | CA2397202A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 07/26/2001 | CA2397065A1 Compositions for delivery of a cortisol antagonist |